Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 1:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 7,451 matching trials from the live ClinicalTrials.gov search.
Filters: Denver, Colorado Clear all
Active, not recruiting Phase 3 Interventional

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

NCT05633602
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Chemotherapy, Pembrolizumab, Ramucirumab
Drug · Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
566
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 442 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Nov 1, 2026, 1:39 AM EDT
Completed No phase listed Observational

Detection of Reductions in Cystic Fibrosis Airway Inflammation While Using Aztreonam Lysine Solution

NCT01736839
View directory record Official record
Conditions
Cystic Fibrosis in Adults, Chronic Colonization With Pseudomonas Aeruginosa
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Nov 1, 2026, 1:39 AM EDT
Completed Phase 4 Interventional

This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.

NCT00380939
View directory record Official record
Conditions
Coronary Arteriosclerosis
Interventions
Atorvastatin, Pravastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
36
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2006 · Synced Nov 1, 2026, 1:39 AM EDT
Completed Phase 4 Interventional

Effects of Carvedilol on Health Outcomes in Heart Failure

NCT00381030
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
carvedilol plus nurse management
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
0 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 27, 2006 · Synced Nov 1, 2026, 1:39 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Consistency of Automated Neuropsychological Assessment Metrics (ANAM) Performance in Those With Deployment Acquired Mild Traumatic Brain Injury (TBI)

NCT01334528
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Post-Concussive Symptoms
Interventions
Not listed
Lead sponsor
VA Eastern Colorado Health Care System
Federal
Eligibility
18 Years to 45 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 15, 2016 · Synced Nov 1, 2026, 1:39 AM EDT
Recruiting Not applicable Interventional

HYDRAFIL-D: HYDRogel Augmentation For Intervertebral Lumbar Discs

NCT06011551
View directory record Official record
Conditions
Degenerative Disc Disease (DDD)
Interventions
The ReGelTec HYDRAFIL™ System, Conservative Care Management
Device · Other
Lead sponsor
ReGelTec, Inc.
Industry
Eligibility
22 Years to 85 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • Santa Monica, California • Walnut Creek, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Nov 1, 2026, 1:39 AM EDT
Completed No phase listed Observational

Study to Evaluate the Human Infection of the Lower Respiratory Tract in Children at High Risk

NCT00192439
View directory record Official record
Conditions
Severe Respiratory Disease
Interventions
High Risk Respiratory Disease
Behavioral
Lead sponsor
MedImmune LLC
Industry
Eligibility
1 Day to 24 Months
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
16
States / cities
Long Beach, California • Denver, Colorado • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated May 7, 2007 · Synced Nov 1, 2026, 1:39 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06430801
View directory record Official record
Conditions
Crohn's Disease
Interventions
IV Tulisokibart, SC Tulisokibart, IV Placebo, SC Placebo
Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years to 80 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
87
States / cities
Dothan, Alabama • Phoenix, Arizona • Sun City, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 1, 2026, 1:39 AM EDT
Completed Not applicable Interventional Results available

Assess Safety and Probable Benefit of the EXCOR® Pediatric Ventricular Assist Device

NCT00583661
View directory record Official record
Conditions
Heart Failure, Cardiomyopathies
Interventions
EXCOR Pediatric
Device
Lead sponsor
Berlin Heart, Inc
Industry
Eligibility
1 Day to 16 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
15
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2013 · Synced Nov 1, 2026, 1:39 AM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

NCT04092283
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
829
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 549 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 1, 2026, 1:39 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

NCT01715805
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo, Antidepressant Therapy (ADT)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,022 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
83
States / cities
Tucson, Arizona • Little Rock, Arkansas • Cerritos, California + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Nov 1, 2026, 1:39 AM EDT
Completed Phase 1 Interventional

Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis

NCT03050151
View directory record Official record
Conditions
Atopic Disorders, Eczema, Atopic
Interventions
Dupilumab, Auto-injector Device, Prefilled syringe
Drug · Device
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
37
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Long Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Nov 1, 2026, 1:39 AM EDT
Completed Phase 3 Interventional Results available

Study of Omiganan 1% Gel in Preventing Catheter Infections/Colonization in Patients With Central Venous Catheters

NCT00231153
View directory record Official record
Conditions
Infection
Interventions
Omiganan 1% gel, Povidone-Iodine 10%
Drug
Lead sponsor
Cadence Pharmaceuticals
Industry
Eligibility
13 Years and older
Enrollment
1,859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
36
States / cities
Mobile, Alabama • Phoenix, Arizona • Arcadia, California + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2009 · Synced Nov 1, 2026, 1:39 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function

NCT01685801
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Placebo-matched-to-ivacaftor tablet
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Nov 1, 2026, 1:39 AM EDT
Terminated Phase 1Phase 2 Interventional

Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

NCT01416428
View directory record Official record
Conditions
Multiple Myeloma, Waldenstrom Macroglobulinemia
Interventions
oprozomib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
19
States / cities
Scottsdale, Arizona • Salinas, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Nov 1, 2026, 1:39 AM EDT
Recruiting Phase 2Phase 3 Interventional

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

NCT04613596
View directory record Official record
Conditions
Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Interventions
Adagrasib, Pembrolizumab
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
220
States / cities
Goodyear, Arizona • Prescott Valley, Arizona • Safford, Arizona + 168 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 1, 2026, 1:39 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes

NCT03298542
View directory record Official record
Conditions
Pre-Symptomatic Type 1 Diabetes
Interventions
Golimumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
6 Years to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Nov 1, 2026, 1:39 AM EDT
Completed Phase 3 Interventional

Using Drug Levels in the Blood to Guide Therapy in HIV Infected Patients Taking a Protease Inhibitor

NCT00041769
View directory record Official record
Conditions
HIV Infections
Interventions
Therapeutic Drug Monitoring (TDM)
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
46
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2010 · Synced Nov 1, 2026, 1:39 AM EDT
Active, not recruiting Phase 3 Interventional

Cisplatin Disposition and Kidney Injury

NCT03817970
View directory record Official record
Conditions
Nephrotoxicity
Interventions
Granisetron, Ondansetron, Palonosetron
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Denver, Colorado • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 1, 2026, 1:39 AM EDT
Completed Phase 3 Interventional Results available

Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer

NCT01547741
View directory record Official record
Conditions
Breast Cancer
Interventions
Doxorubicin, Cyclophosphamide, Docetaxel, Paclitaxel
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
4,242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
914
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 612 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Nov 1, 2026, 1:39 AM EDT
Completed Not applicable Interventional Results available

Hemodynamic-GUIDEd Management of Heart Failure

NCT03387813
View directory record Official record
Conditions
Heart Failure, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV, Heart Failure，Congestive, Heart Failure With Reduced Ejection Fraction, Heart Failure With Normal Ejection Fraction, Heart Failure; With Decompensation
Interventions
CardioMEMS™ HF System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
125
States / cities
Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 100 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Nov 1, 2026, 1:39 AM EDT
Completed Not applicable Interventional Results available

Combining Mechanisms for Better Outcomes (COMBO)

NCT03689920
View directory record Official record
Conditions
Chronic Pain, Back Pain
Interventions
Boston Scientific Spectra WaveWriter™ Spinal Cord Stimulation (SCS) System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
22 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Phoenix, Arizona • La Jolla, California • Greenwood Village, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Nov 1, 2026, 1:39 AM EDT
Active, not recruiting Not applicable Interventional Results available

PROACTIVE-HF IDE Trial Heart Failure NYHA Class III

NCT04089059
View directory record Official record
Conditions
Heart Failure NYHA Class III
Interventions
Cordella™ Pulmonary Artery Sensor System
Device
Lead sponsor
Endotronix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
70
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Nov 1, 2026, 1:39 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C

NCT00336479
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a, Placebo
Drug · Other
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
36
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Nov 1, 2026, 1:39 AM EDT